Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: China National Study of Adrenal Venous Sampling Primary completion pushed from Dec 30, 2026 to Aug 31, 2028 Chinese Academy of Medical Sciences, Fuwai HospitalNot specified NCT06192238
  2. Notable: Thermoses as a Way to Provide Human Milk to Toddlers in Daycare Primary completion pushed from Nov 2026 to Nov 2027 University of FloridaNot applicable NCT07540871
  3. Notable: Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia · Hepatocellular Carcinoma Primary completion pushed from Nov 22, 2025 to Nov 22, 2027 CHU de ReimsNot applicable NCT06475118
  4. Notable: Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI Primary completion pushed from Aug 31, 2026 to Mar 31, 2027 University of BirminghamNot applicable NCT06465901
  5. Notable: Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2028 M.D. Anderson Cancer CenterNot applicable NCT05676450
  6. Notable: NEPTUNE Match Study Primary and study completion pushed from Dec 30, 2029 to Dec 30, 2030 University of MichiganNot applicable NCT04571658
  7. Notable: Mechanisms of Resistance Exercise Training for Improved Muscle Insulin Sensitivity Primary completion pushed from Aug 31, 2028 to Sep 1, 2029 Mayo ClinicNot applicable NCT07128368
  8. Notable: Continuous Supraglottic Oxygen Insufflation Via Video Laryngoscope Blade on Apneic Oxygenation During Tracheal Intubation Under General Anesthesia Primary completion pushed from Jun 22, 2026 to Jul 1, 2029 Affiliated Hospital of Jiaxing UniversityNot applicable NCT07662304
  9. Notable: KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) Recruitment opened Endo USA Inc., a Keenova Therapeutics CompanyPhase 3 NCT07846280
  10. Notable: Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) Recruitment opened Viking Therapeutics, Inc.Phase 3 NCT07868835
  11. Notable: Oral VK2735 for Weight Management · Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) Recruitment opened Viking Therapeutics, Inc.Phase 3 NCT07868939
  12. Notable: ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular Recruitment opened Suzhou Zelgen Biopharmaceuticals Co.,LtdPhase 3 NCT07813572
  13. Notable: GFH276 · RAS-Mutant Advanced Solid Tumors Recruitment opened Genfleet Therapeutics (Shanghai) Inc.Phase 1/2 NCT07198321
  14. Notable: BBM-C101 Injection · Cervical High-Grade Squamous Intraepithelial Lesion(HSIL) Recruitment opened Shanghai Mianyi Biopharmaceutical Co., Ltd.Phase 1/2 NCT07668960
  15. Notable: RO7821657 · Solid Tumors Recruitment opened Hoffmann-La RochePhase 1 NCT07883577
  16. Notable: Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants Recruitment opened Chengdu Zenitar Biomedical Technology Co., LtdPhase 1 NCT07809217
  17. Notable: Post Market Study of the Flexagon Only System and Flexagon Plus OTOLoc for Creation of Side-to-Side Duodeno-Ileal Diversion & Flexagon Plus OTOLoc Self Forming Magnet (SFM) System for Creation of Side-to-Side Jejunum-Jejunum and Ileal-Ileal Anastomoses Recruitment opened GI Windows, Inc.Not applicable NCT07695558
  18. Notable: GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study Recruitment opened Noom Inc.Not specified NCT07588984
  19. Notable: Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy Recruitment opened UNCANCER LLCNot applicable NCT07885033
  20. Notable: Decision Counseling and Follow-up for Shield+ Patients Recruitment opened Guardant Health, Inc.Not specified NCT07620535
  21. Notable: First-Line Lenvatinib in Child-Pugh B · HCC Unsuitable for Curative Treatment Recruitment opened National Cancer Center, KoreaPhase 2 NCT07297654
  22. Notable: Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast Recruitment opened National Institute of Neurological Disorders and Stroke (NINDS)Phase 1 NCT07796360
  23. Notable: PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study Recruitment opened University of FloridaPhase 3 NCT07670650
  24. Notable: Targeting Lifestyle to Improve Colorectal Cancer Screening Recruitment opened Norwegian Institute of Public HealthNot applicable NCT07135115
  25. Notable: Povidone Iodine for Caries Prevention Enrolling by invitation only Jeffrey A. BanasPhase 3 NCT07741409